Annals of Oncology - current issue,
- 1680PA global patient-driven Facebook study in a very rare sarcoma: Health-related quality of life in epithelioid hemangioendothelioma (EHE) patients
AbstractBackgroundEHE is a vascular sarcoma with an incidence of ≤ 1 per 1 million/year, and an unpredictable clinical course with significant symptom burden. Recruiting EHE patients for studies is difficult and health-related quality of life (HRQoL) in these patients is unknown. We aimed to study the impact of EHE symptom burden on HRQoL.MethodsThe study was initiated after EHE patients’ foundations approached our research group to study HRQoL. - 1607PDeprescribing potentially inappropriate medication in cancer patients
AbstractBackgroundDue to their advanced age many cancer patients with unfavorable prognosis suffer from comorbidities, and thus the risk of consuming potentially inappropriate medication (PIM). It is vital to deprescribe drugs with potential harmful effects or no short-term benefit for lowering pill.Hence, we examined the degree of deprescription of potentially inappropriate medication (PIM) in patients suffering from cancer.MethodsRetrospective, - 1576PEfficacy results of selective AXL inhibitor bemcentinib with pembrolizumab following chemo in patients with NSCLC
AbstractBackgroundThe RTK AXL is implicated in epithelial-to-mesenchymal transition, negative regulation of anti-tumor immunity and resistance to multiple therapies including CPIs. Bemcentinib is a first-in-class, oral, highly selective and potent AXL inhibitor which has been demonstrated to enhance anti-PD1 therapy in the pre-clinical setting.MethodsThis PhII trial enrolled 48 advanced lung adenocarcinoma pts with progression on or after 1 prior - 513PThe expression of versican and its role in pancreatic neuroendocrine tumour
AbstractBackgroundPancreatic neuroendocrine tumor (pNET) is rare and heterogeneous. New biomarkers are needed for better predicting the prognosis and providing individualized treatment. Versican (VCAN) plays an important role in tumorigenesis. Our previous study showed VCAN was specifically expressed in pNET tumor tissue. Therefore, we planned to investigate the role of VCAN in pNET prognosis.MethodsClinical and pathological data of pNET patients - 1629O_PRThe price of added value for new anti-cancer drugs in France 2004-17
AbstractBackgroundThe cost of new cancer medications is increasing prompting clinicians and policymakers to ask if newer therapies are worth their cost. We evaluated the relation between the price of new cancer drugs and their added therapeutic benefit measured by France’s High Authority of Health (HAS) and the European Society for Medical Oncology (ESMO).MethodsWe studied drugs to treat solid tumors registered by the European Medicines Agency (E - 1132PRisk and impact of renal impairment of locally advanced head and neck squamous cell carcinoma patients who received chemoradiotherapy with cisplatin
AbstractBackgroundRisk factors of cisplatin induced acute kidney injury (AKI) patients has been well described. In HNSCC, an incidence of cisplatin induced AKI was observed in 34.2%. Most studies reported AKI as a surrogate endpoint. However, delayed cisplatin induced nephrotoxicity and long-term renal outcomes were not well studied.MethodsLocally advanced HNSCC patients treated between 1/2007 and 12/2018 who underwent definitive or post-operativ - 1575PPreliminary results from phase Ib study of spartalizumab plus chemotherapy for advanced non-small cell lung cancer (NSCLC)
AbstractBackgroundSpartalizumab (PDR001) is an anti-PD-1 monoclonal antibody that is been explored in different tumor types. Preliminary safety and efficacy results from Groups B (B) and C (C) of a phase Ib study investigating spartalizumab with platinum-based chemotherapy in PD-L1 unselected advanced NSCLC (NCT03064854) are reported here.MethodsTreatment-naive, stage IIIB/IV NSCLC, EGFR/ALK/ROS-1(-) pts, PS 0-1, were assigned to B (non-squamous - 63PStudy of photodynamic therapy in vitro
AbstractBackgroundPhotosensitizers (PS) are commonly used in photodynamic therapy to treat skin cancer. PS molecules bind to cell membrane and damage it by singlet oxygen (SO) generated under illumination. In our laboratory, we study in vitro the processes involved in photodynamic therapy on a model bilayer lipid membranes (BLM) by measuring the boundary potential applying the Intramembrane Field Compensation Method (Sokolov and Kuz’min, Biofizik - LBA86Mirtazapine in cancer-associated anorexia cachexia: A randomised, double-blind, placebo-controlled trial
AbstractBackgroundThe available options to manage cancer-associated anorexia-cachexia syndrome (CACS) are limited. At standard doses, the tetracyclic antidepressant mirtazapine causes appetite stimulation and weight gain. Based on limited evidence, it is used in cancer-associated anorexia. This trial was conducted to assess the efficacy and safety of mirtazapine in patients with CACS.MethodsA double-blind randomized placebo-controlled trial. Incl - 1171PThe humanistic burden reported by patients diagnosed with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) in Europe
AbstractBackgroundR/M SCCHN is associated with poor prognosis and low survival rate. Further, there is a lack of evidence of how the disease impacts patients’ quality of life (QoL) and ability to perform activities of daily living (ADL). This study examines patients’ experience of living with R/M SCCHN.MethodsA cross-sectional study was conducted in the EU5 from Jan to May 2019. Medical oncologists recruited patients to complete a survey, includi - LBA15_PRA phase III trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with carcinomas of an unknown primary (CUP) site (GEFCAPI 04)
AbstractBackgroundCUP are heterogeneous tumors that share the unique characteristic of metastases with no identifiable origin. The outcome of patients (pts) with CUP is poor despite empiric chemotherapy that has activity against a wide variety of neoplasms such as the cisplatin-gemcitabine combination (Culine S, JCO 2002). Molecular tests may identify primary sites in up to 80% of pts, and results suggest that at least 1/3 of identified primaries - 1145PApatinib in treating patients with platinum-resistant or platinum-refractory recurrent or metastatic nasopharyngeal carcinoma
AbstractBackgroundTo evaluate the efficacy and safety of apatinib in treating patients with platinum-resistant or platinum-refractory recurrent or metastatic nasopharyngeal carcinoma.MethodsIn this phase 2, single-arm, prospective study, we recruited patients aged 18–65 years with platinum-resistant or platinum-refractory recurrent /metastatic nasopharyngeal carcinoma. Patients were treated with apatinib at an initial dose of 500 mg once daily an - 1574PSurvival prolongation by rationale innovative genomics (SPRING): An international WIN consortium phase I study exploring safety and efficacy of avelumab, palbociclib, and axitinib in advanced non-small cell lung cancer (NSCLC) with integrated genomic and transcriptomic correlates
AbstractBackgroundIn prior published work, the Worldwide Innovative Network (WIN) Consortium described the Simplified Interventional Mapping System (SIMS) algorithm, based on the hypothesis that both genomic and transcriptomic data are important for matching to a tri-therapy regimen. To account for variation in transcription levels between different tissues, gene by gene tumor RNA levels are normalized against RNA levels in analogous biopsied nor - 340PDose-escalation study of G1T48, an oral selective estrogen receptor degrader (SERD), in postmenopausal women with ER+/HER2- locally advanced or metastatic breast cancer (ABC)
AbstractBackgroundThe SERD fulvestrant is a well-established therapy for ER+/HER2- ABC. However, its intramuscular route of administration may be painful and limits systemic exposure. G1T48 is a highly potent and efficacious oral SERD in both mutant and WT ESR1 preclinical models with the potential to achieve higher exposure and provide clinical benefit in patients with ER+ ABC.MethodsPostmenopausal women with ER+/HER2- ABC following progression - LBA85Longitudinal circulating tumour DNA (ctDNA) monitoring for early detection of disease progression and resistance in advanced NSCLC in FLAURA
AbstractBackgroundIn the phase III FLAURA study (NCT02296125), the 3rd-generation EGFR-TKI osimertinib showed superior efficacy to comparator EGFR-TKIs in previously untreated EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC). Here we report results from an exploratory analysis of ctDNA for the early detection of disease progression (PD) in FLAURA.MethodsTreatment-naïve patients (pts) with EGFRm (ex19del/L858R) locally advanced/met - 536PA prospective study of diffusion-weighted magnetic resonance imaging for predicting outcome following chemoradiotherapy, in squamous cell carcinomas of the anus
AbstractBackgroundAnal Squamous Cell Carcinoma (ASCC) is radically treated by chemoradiotherapy (CRT). The use of DW-MRI as a predictive marker of outcome would enable early individualisation of treatment. We aimed to quantify the changes in mean apparent-diffusion-coefficient (ADCMean) between a DW-MRI at diagnosis and on fraction 8-10 of CRT as a biomarker for cellularity, and correlate these with outcome.MethodsThis prospective study recruited - 1983PD_PRComprehensive genomic profiling (CGP) of carcinoma of unknown primary origin (CUP): Retrospective molecular classification of potentially eligible patients (pts) for targeted or immunotherapy treatment (tx) using the prospective CUPISCO trial’s criteria
AbstractBackgroundStandard CUP therapy has not changed for decades. CUPISCO (NCT03498521) is an ongoing randomised prospective trial using CGP to assign CUP pts to individualised targeted or immunotherapy arms (molecularly guided therapy; MGT).MethodsArchival tissue from 303 centrally reviewed undifferentiated- and adeno-CUP cases in the FoundationCore™ database underwent hybrid capture-based CGP (FoundationOne® CDx). Microsatellite instability ( - 523OFOxTROT: An international randomised controlled trial in 1053 patients evaluating neoadjuvant chemotherapy (NAC) for colon cancer. On behalf of the FOxTROT Collaborative Group
AbstractBackgroundNAC has an established role in many solid tumours but its utility has not previously been formally evaluated in colon cancer.MethodsPts with CT-staged T3-4 N0-2 M0 colon cancer were randomised in a 2:1 ratio to pre-and-postoperative (NAC/AC) or postoperative (control) FOLFOX chemotherapy. Total planned chemotherapy was the same in both arms, but NAC/AC pts received the first 6 weeks before surgery. Pts with RAS-wt tumours could - 1573PWeekly epirubicin as palliative treatment in elderly patients with malignant pleural mesothelioma
AbstractBackgroundMalignant pleural mesothelioma (MPM) is a rapidly progressive tumor with a poor prognosis. The benefit of first-line standard pemetrexed – platinum chemotherapy in MPM has been established. Currently, second-line chemotherapy is increasingly use, because many patients are fit at the progression of the disease. No standard second/further line chemotherapy exit for MPM after failure of first-line pemetrexed based chemotherapy. Thi - 506PTPX-0046 is a novel and potent RET/SRC inhibitor for RET-driven cancers
AbstractBackgroundOncogenic activation of the receptor tyrosine kinase (RTK) RET via point mutation or genomic rearrangement has been identified in multiple cancers, including medullary and papillary thyroid cancers, and non-small cell lung cancer (NSCLC). Two multi-kinase RET inhibitors vandetanib and cabozantinib have been approved for thyroid cancer. Current investigational RET inhibitors BLU-667 and LOXO-292 have demonstrated efficacy in RET - LBA93Registrational results of LOXO-292 in patients with RET-altered thyroid cancers
AbstractBackgroundTo date, no targeted therapy is approved for patients with RET-altered cancers. LOXO-292 is a highly selective RET inhibitor with activity across known oncogenic RET fusions and mutations. Based on initial data from LIBRETTO-001, LOXO-292 received FDA Breakthrough Designation for the treatment of RET fusion+ non-small cell lung cancer (NSCLC), RET fusion+ thyroid cancer and RET-mutant medullary thyroid cancer (MTC).MethodsThe LI - 274PIdentification of GSTP1 transferred by extracellular vesicles responsible for adriamycin-resistance in breast cancer cells
AbstractBackgroundAnthracycline/taxane-based chemotherapy is frequently used to treat breast cancer. However, not all patients respond to chemotherapy due to naturalor acquired chemo-resistance. Glutathione S-transferase P1(GSTP1), which belongs to the family of phase II metabolic enzymes, has been reported to function in detoxifying several anti-cancer drugs by conjugating them with glutathione.MethodsWe identified GSTP1 as a drug-resistance-rel - LBA84Primary results from TAIL, a global single-arm safety study of atezolizumab (atezo) monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer (NSCLC)
AbstractBackgroundAtezo treatment (tx) has demonstrated improved survival and a manageable safety in advanced NSCLC. TAIL (NCT03285763) is a phase III/IV study evaluating the safety and efficacy of atezo in patients (pts) with previously treated advanced NSCLC, including those who are generally excluded from pivotal trials.MethodsTAIL enrolled pts with Stage IIIb/IV NSCLC who experienced disease progression after 1-2 lines of standard chemotherap - 22PXAF1 and ZNF313 complex stimulates ER stress-induced apoptosis via direct GRP78 inhibition
AbstractBackgroundEndoplasmic reticulum (ER) stress-induced, unfolded protein response (UPR)-mediated apoptosis is a protective mechanism whose failure contributes to malignant tumor progression. XAF1 is a stress-inducible, pro-apoptotic tumor suppressor which is inactivated in many human tumor cells. The molecular signal mechanism explaining its function in controlling ER stress, however, remains largely unclear. In this study, we explored the r - 1572PA prospective phase II trial of carboplatin (CBDCA) and nab-paclitaxel (nabPTX) for advanced non-small cell lung cancer (NSCLC) with interstitial lung disease (ILD)
AbstractBackgroundBecause of the high risk of exacerbation of ILD, patients with concomitant advanced NSCLC and ILD have been excluded from most clinical trials of chemotherapy, despite around 10% of all NSCLC cases. This study prospectively evaluated the efficacy and safety of nab-paclitaxel in combination with CBDCA in advanced NSCLC patients with ILD.MethodsEnrolled patients had treatment-naïve, advanced NSCLC with ILD. Patients received 100 m - 246PTriple blinded prospective study assessing the impact of genomics & artificial intelligence Watson for oncology (WFO) on MDT’s decision of adjuvant systemic therapy for hormone receptor positive early breast carcinoma
AbstractBackgroundDecision on adjuvant systemic therapy in hormone positive early breast carcinoma is the only grey area in breast carcinoma management. This study was done to investigate the concordance between the results of genomic test(Endopredict), artificial intelligence(Watson For Oncology,WFO) and tumor board decision and implications of the same in clinical practice.MethodsThis was a triple blinded, prospective study. Decision regarding - LBA92Switch maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma: A multicenter open label phase II trial (NVALT19)
AbstractBackgroundAll malignant mesothelioma (MM) patients progress after first-line therapy. We examined whether switch maintenance gemcitabine in patients, who did not show progression after first-line platinum-pemetrexed, could prolong time to disease progression.MethodsNVALT19 was an open label, randomized phase II trial, conducted in The Netherlands. Main eligibility criteria were pathologically proven MM, ECOG-PS 0-2 and completion of 4-6 c - 85PImproving detection level of somatic mosaicism in neurofibromatosis type 1
AbstractBackgroundNeurofibromatosis type 1 (NF-1) is a tumor predisposition syndrome resulting from mutations in NF1 antioncogene. Differential diagnosis with genetic testing is essential in NF-1 diagnostics due to its clinical variability. Identifying of pathogenic mutations is challenging because of the gene size and structure, especially for low-level somatic mosaicism. Notably, patients with mosaic NF-1 demonstrate no less severe phenotype th - LBA83Final efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC)
AbstractBackgroundbTMB assays determine TMB using a noninvasive blood test. B-F1RST (ITT, n = 152) is the first prospective trial to evaluate bTMB as a biomarker to predict benefit of 1L atezo monotherapy in advanced NSCLC. bTMB high (score of ≥ 16; ≥ 14.5 mut/Mb) predicted better ORR with atezo vs bTMB low (< 16; 28.6% vs 4.4%) in the biomarker evaluable population (BEP) with ≥ 6 mo follow up in the primary analysis. Numerical benefit for bTMB h - 78PUrine cell-free and extracellular vesicle cargo miRNAs as biomarkers for prostate cancer diagnosis
AbstractBackgroundProstate cancer (PCa) is one of the major cancers in men, but discrepancy between incidence and mortality calls for a careful approach to screening and diagnosis. Controversy between US Preventive Services Task Force recommendations and the outcomes clinical trials illustrate that the shortcomings of existing biomarkers and high demand in novel approaches for prostate cancer screening. Recent studies have suggested miRNAs as new - 1571PPredicting chemotherapy toxicity in elderly patients with advanced non-small cell lung cancer: A prospective multicenter study of the National Hospital Organization in Japan
AbstractBackgroundPrevious studies have developed risk stratification schemas to assess chemotherapy toxicity. However, it is controversial which geriatric assessment variables should be used to assess the individual risk of severe toxicity from chemotherapy in elderly patients.MethodsPatients aged ≥70 years with advanced non-small cell lung cancer (NSCLC) treated at 24 National Hospital Organization institutions completed a pre-1st-line chemother - 329PComparative effectiveness of palbociclib plus letrozole vs letrozole for metastatic breast cancer in US real-world clinical practices
AbstractBackgroundPalbociclib, the first clinically available oral CDK4/6 inhibitor, in combination with endocrine therapy has become standard of care for HR+/HER2- advanced/metastatic breast cancer (MBC). No real-world studies have examined relative effectiveness of palbociclib plus endocrine therapy compared with endocrine therapy alone. This study compared real-world progression free survival (rwPFS) of palbociclib plus letrozole (PB+LE) vs le - LBA91_PRA multicentre randomized phase III trial comparing pembrolizumab (P) vs single agent chemotherapy (CT) for advanced pre-treated malignant pleural mesothelioma (MPM): Results from the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial
AbstractBackgroundMPM is an aggressive malignancy of increasing prevalence and poor prognosis. At relapse after platinum-based (pb) CT, single agent CT is commonly used and single arm trials of immune checkpoint inhibitors have demonstrated encouraging activity.MethodsPROMISE-meso is an open-label 1:1 randomized phase III trial investigating the efficacy of P (200 mg/Q3W) vs institutional choice single agent CT (gemcitabine or vinorelbine) in rel - 321PClinical application of mutational analysis in breast cancer patients: The relevance of PIK3CA analysis for precision medicine
AbstractBackgroundThe identification of biomarkers to drive treatment is one of the most important objectives of precision medicine. During last years, the role of PIK3CA mutations have been related to clinical benefit deriving from treatment with PI3K, and mTOR inhibitors. In breast cancer (BC), PIK3CA mutations are widely present and the use, in clinical trials, of selective inhibitors improved clinical outcomes. The aim of this study is to ass - LBA82Pembrolizumab (pembro) + chemotherapy (chemo) in metastatic squamous NSCLC: Final analysis and progression after the next line of therapy (PFS2) in KEYNOTE-407
AbstractBackgroundIn the randomized KEYNOTE-407 study (NCT02775435), pembro + carboplatin and paclitaxel/nab-paclitaxel (chemo) significantly improved OS, PFS, and ORR compared with placebo + chemo in patients (pts) with previously untreated metastatic squamous NSCLC. Benefit was observed irrespective of PD-L1 TPS. We report updated OS from the protocol-specified final analysis and, for the first time, PFS2.MethodsEligible pts were randomized 1:1 - 60PSensitization of estrogen receptor-positive breast cancer cells to tamoxifen by novel epi-oligomycin A
AbstractBackgroundBreast cancer is the most common cancer in women. Most breast tumors are ER(+)/hormone-dependent, this makes it possible to treat them with tamoxifen and other SERM/SERD drugs. Combination treatment of tamoxifen with novel drugs provides an efficient way for reduction of the drug concentration. The aim of the work was to obtain novel less toxic oligomycin derivatives for combinatorial treatment with tamoxifen.MethodsOligomycin A - 1570PPioglitazone and clarithromycin combined with metronomic low-dose chemotherapy versus nivolumab in patients with advanced non-small cell lung cancer treated in 2nd-line and beyond: Outcomes from a randomized phase II trial (ModuLung)
AbstractBackgroundThe ModuLung trial addresses the medical need for low-toxic therapies in frequently comorbid patients with relapsed or refractory non-small cell lung cancer (NSCLC). We evaluated safety and efficacy of a biomodulatory approach in > =2nd-line, aiming for induction of anakoinosis i.e. communicative reprogramming of dysregulated cellular and intercellular homeostasis.MethodsPatients with stage IIIB/IV squamous or non-squamous NSCLC - 297PLack of benefit of neoadjuvant pertuzumab in high risk HER2 positive breast cancer: A retrospective case-control study of 355 cases with biomarker analysis
AbstractBackgroundThe NEOSPHERE trial suggested that pertuzumab (P) added to a combination of docetaxel and trastuzumab (T) as a neoadjuvant therapy in HER2 positive breast cancer (HER2+ BC) patients (pts) significantly enhances pathological complete response (pCR) rates. Here, we report our institution experience, focusing on stage III tumors.MethodsWe reviewed clinical and pathological response (residual cancer burden, RCB) in 355 HER2+ BC trea - LBA90Primary analysis results of randomized controlled trial evaluating reactive topical corticosteroid strategies for the facial acneiform rash by EGFR inhibitors (EGFRIs) in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC): FAEISS study
AbstractBackgroundThe management strategies regarding the strength of reactive topical corticosteroids have not been well evaluated in clinical trials. This FAEISS study is designed to confirm the superior efficacy of reactive topical corticosteroid strategies with serially ranking-DOWN from very strong levels compared with those with serially ranking-UP from weak levels for facial acneiform rash induced by EGFRI.MethodsPts with RAS wt mCRC were - 1634PDCost avoided in drugs derived from participation in clinical trials in colorectal cancer
AbstractBackgroundColon cancer presents at high incidence and its treatment generates an important economic impact in hospitals. In Spain, it is mandatiory for the sponsors of clinical trials to supply the investigational drugs without charge to the national health system. Avoided cost is defined as the cost that would have had to be paid if the patient did not participate in a clinical trial with the free contribution of the drugs. The objective - LBA81_PRPhase II/III blood first assay screening trial (BFAST) in patients (pts) with treatment-naïve NSCLC: Initial results from the ALK+ cohort
AbstractBackgroundTissue-based assessment of actionable mutations in pts with NSCLC is limited by invasive biopsies and adequacy of biopsied tumour material. Blood-based testing may overcome such limitations, allowing multiplex profiling in a single test. BFAST (NCT03178552) is an ongoing multicentre, open-label, multi-cohort study evaluating the relationship between blood-based next-generation sequencing (NGS) detection of actionable genetic alt - 503PEPI-7386 is a novel N-terminal domain androgen receptor inhibitor for the treatment of prostate cancer
AbstractBackgroundThe androgen receptor (AR) pathway drives most metastatic castration-resistant prostate cancers (mCRPC) even in late stages of the disease. Anti-androgen resistance mechanisms include AR gene amplification, C-terminal ligand-binding domain (LBD) mutations and expression of constitutively-active truncated AR splice variants lacking the LBD (eg. AR-V7). Selective inhibition of the N-terminal domain (NTD) of the AR can inhibit its’ - 1569PFinal results of randomized phase II trial of metronomic vs weekly oral vinorelbine (OV) as first-line chemotherapy (CT) in advanced NSCLC patients unfit to platinum-based CT (P-CT): Tempo-Lung
AbstractBackgroundMetronomic chemotherapy (CT) is a therapeutic strategy based on a regular, short interval, fixed-dose schedule developed to improve disease control and reduce toxicity. Metronomic oral vinorelbine (m-OV) showed promising results. The trial randomly compared single agent m-OV vs OV standard schedule as first-line treatment in advanced NSCLC patients (pts) unfit for platinum-based CT (P-CT).MethodsCT naive pts with advanced NSCLC - 496PPredictors for early trial discontinuation of patients with cancer participating in phase I clinical trials
AbstractBackgroundPatients with cancer who are refractory to standard treatments may participate in phase I clinical trials. Despite stringent eligibility criteria for trial participation, early discontinuation often occurs. These patients do not benefit from study treatment and may experience additional burden from participation, while adequate evaluation of novel treatment strategies is hampered. The aim of this study was to identify predictors - LBA89PD-L1 expression, patterns of progression and patient-reported outcomes (PROs) with durvalumab plus platinum-etoposide in ES-SCLC: Results from CASPIAN
AbstractBackgroundIn the phase III CASPIAN trial, durvalumab (D) in combination with etoposide plus either cisplatin or carboplatin (EP) significantly improved the primary endpoint of OS vs EP alone in pts with extensive-stage small-cell lung cancer (ES-SCLC). Here we describe clinically relevant analyses for D + EP vs EP based on PD-L1 expression, progression patterns and PROs.MethodsTx-naive ES-SCLC (WHO PS 0/1) pts received 4 cycles of EP plus - 487PComparison of intratumoral docetaxel exposure in cancer patients between nanoparticle entrapped docetaxel (CPC634) and conventional docetaxel (Cd): The CriTax study
AbstractBackgroundIneffective chemotherapy may partly be caused by subtherapeutic intratumoral drug levels. Nanomedicines are developed to improve the therapeutic index, by increasing intratumoral drug exposure and preserving healthy tissue. CPC634 is a new nanoparticle entrapping docetaxel. Here, we hypothesized that CPC634 increases intratumoral docetaxel level and overall duration of exposure.MethodsIn this randomized cross-over study we asses - LBA80Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) for metastatic NSCLC: Tissue TMB (tTMB) and outcomes in KEYNOTE-021, 189, and 407
AbstractBackgroundPembro + chemo improves efficacy as 1L therapy for metastatic squamous and nonsquamous NSCLC, regardless of PD-L1 TPS. We explored the relationship between tTMB and efficacy in KEYNOTE-021 C and G (nonsquamous; NCT02039674), 189 (nonsquamous; NCT02578680), and 407 (squamous; NCT02775435).MethodstTMB was determined by whole-exome sequencing of tumor and matched normal DNA. For each study, the association of tTMB (continuous log10 - 481PBioavailability of tepotinib: Impact of omeprazole and food
AbstractBackgroundAcid-inhibitory drugs (e.g. proton pump inhibitors - PPIs) increase intragastric pH, which may decrease solubility, bioavailability, and efficacy of oral cancer drugs. Furthermore, polypharmacy in cancer patients is common and different requirements for treatment with or without food can impact compliance. Tepotinib is an oral, highly selective MET inhibitor being investigated in patients with solid tumors with MET dysregulation - 234PEffects of supervised and adapted exercise program in the quality of life and strength of breast cancer survivors: MAMA MOVE Gaia trial
AbstractBackgroundTreatments for early breast cancer have side effects that affect quality of life (QoL) and cause deconditioning. Physical exercise might have a supportive and coadjuvant role in the rehabilitation of breast cancer survivors. We aimed to analyse the preliminary results of a community-based supervised exercise training program on QoL and muscle strength in breast cancer survivors.MethodsTwenty breast cancer female survivors were r - 475PA phase IIa clinical trial combining ALRN-6924 and palbociclib for the treatment of patients with tumours harboring wild-type p53 and MDM2 amplification or MDM2/CDK4 co-amplification
AbstractBackgroundALRN-6924 is a stabilized, cell-permeating alpha-helical peptide that mimics the p53 tumor suppressor protein to disrupt p53’s interactions with its endogenous inhibitors, MDM2 and MDMX. ALRN-6924 has been evaluated in > 175 cancer patients and demonstrated single-agent activity and a well-tolerated single-agent safety profile. MDM2 amplification is an oncogenic event found in up to 4% of all cancers. Co-amplification of MDM2 an - LBA88Results of the randomized, placebo (PL)-controlled phase II study evaluating the efficacy and safety of regorafenib (REG) in patients (pts) with locally advanced (LA) or metastatic relapsed chondrosarcoma (CS), on behalf of the French Sarcoma Group (FSG) and UNICANCER
AbstractBackgroundREGOBONE, a non-comparative phase II, double-blind, PL-controlled trial was designed to evaluate the activity of REG, an oral multikinase inhibitor, in four parallel independent bone sarcomas cohorts: osteosarcoma, Ewing sarcoma, chondrosarcoma, and chordoma. REG demonstrated promising activity in the osteosarcoma cohort (Lancet Oncol 2019). We report here the CS cohort results.MethodsEligible CS pts were randomized (2:1) to rec - 1141PLong-term results of phase II trial of reduced modified clinical target volume in low-risk nasopharyngeal carcinoma treated with intensity modulated radiotherapy
AbstractBackgroundIntensity modulated radiation therapy (IMRT) is the standard of care for nasopharyngeal carcinoma (NPC). Part of the IMRT quality assurance process involves accurate target volume delineation, which is crucial for local control and survival. Current practice utilizes a uniform contouring method for clinical target volume (CTV) for all stages of NPC. Here, we conducted a single-arm phase 2 trial investigating the tumor control ra - LBA79Association between tissue TMB (tTMB) and clinical outcomes with pembrolizumab monotherapy (pembro) in PD-L1-positive advanced NSCLC in the KEYNOTE-010 and -042 trials
AbstractBackgroundIn randomized open-label trials, pembro monotherapy demonstrated an OS benefit vs chemo in pts with previously treated (KEYNOTE-010, NCT01905657) or treatment naïve (KEYNOTE-042, NCT02220894), PD-L1 + (TPS ≥1%), advanced NSCLC. Associations between tTMB and efficacy were retrospectively explored in a subset of pts with evaluable tTMB in these trials.MethodstTMB was determined by whole exome sequencing of tumor and matched normal - 242PClinical validation of CanAssist breast in a Spanish cohort
AbstractBackgroundCanAssist-Breast (CAB) is a prognostic test for predicting risk of distant recurrence within five years in hormone receptor positive early stage breast cancer patients. It is unique in that the test uses immunohistochemistry coupled with a support vector machine learning based algorithm to predict risk score and category (High or Low). It has been developed and validated on a mix of Asian and Caucasian patients. The test has bee - 1568PPost progression survival for patients treated with docetaxel/nintedanib in the SENECA trial
AbstractBackgroundThe SENECA trial showed similar progression free survival (PFS) and overall survival (OS) in non-squamous non-small cell lung cancer (nsNSCLC) patients (pts) treated with second-line docetaxel/nintedanib, regardless relapsing-time from end of first-line chemotherapy and docetaxel schedule employed (weekly or q3wks) [presented at AIOM 2018]. Because of the lack of data about optimal therapeutic algorithms for nsNSCLC pts and the - 1631PD_PRClinical benefit and prices of cancer drugs in the US and Europe
AbstractBackgroundGiven rising cancer drug costs, US Medicare recently proposed to tie some drug prices to average prices paid by comparable countries. To understand the potential scope of this policy, we assessed differences in cancer drug prices in the US and European countries. We also evaluated the correlation between drug prices and their clinical benefit, as measured by two value frameworks: the American Society of Clinical Oncology Value F - 233PNumber of deliveries as a prognostic factor in different breast cancer subtypes
AbstractBackgroundSome registry-based and population-based studies have suggested that high parity could be an adverse prognostic factor in luminal breast cancer, although the definition of breast cancer subtypes has been varied and prospective studies are lacking.MethodsWe report long-term follow-up (median 8.5 years) from prospectively collected single-institution material of early breast cancers. The patients (n = 612) were treated with modern - 342PAlpelisib (ALP) + fulvestrant (FUL) in hormone-receptor positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC): Subgroup analysis by presence of visceral metastasis (VM) in the SOLAR-1 trial
AbstractBackgroundApproximately 40% of patients (pts) with HR+, HER2– BC have mutations (mut) in PIK3CA with hyperactivation of the PI3K pathway and relative endocrine resistance. In the phase 3 SOLAR-1 trial, treatment with the α-selective PI3K inhibitor ALP with FUL significantly prolonged progression-free survival (PFS) vs placebo [PBO] + FUL in the PIK3CA-mut cohort (median PFS [mPFS], 11.0 vs 5.7 mo; HR 0.65; P < 0.001). Here, we report data - LBA5_PROsimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis
AbstractBackgroundOsimertinib is a 3rd-generation, irreversible, oral EGFR-TKI that potently and selectively inhibits both EGFR-mutated (EGFRm) and EGFR T790M resistance mutations, and has demonstrated efficacy in NSCLC CNS metastases. In the phase III FLAURA study (NCT02296125), osimertinib resulted in significant progression-free survival (PFS) benefit (primary endpoint; datacut off [DCO] 12 June 2017) over comparator EGFR-TKI (HR 0.46, p < 0.0 - 338PReal-world effectiveness of first-line palbociclib + letrozole for metastatic breast cancer 4 years post approval in the US
AbstractBackgroundIn Feb 2015, palbociclib plus letrozole (P+L) became the first cyclin-dependent-kinase 4/6 inhibitor approved for mBC/aBC in the US. Until now, long-term outcomes studies have included a limited number of patients receiving P+L. The objective of this study is to describe real-world patient characteristics and clinical effectiveness associated with P+L as initial endocrine-based therapy use 4 years post approval.MethodsAdult post - LBA87INVICTUS: A phase III, interventional, double-blind, placebo-controlled study to assess the safety and efficacy of ripretinib as ≥ 4th-line therapy in patients with advanced gastrointestinal stromal tumors (GIST) who have received treatment with prior anticancer therapies (NCT03353753)
AbstractBackgroundRipretinib is a switch-control kinase inhibitor that broadly inhibits KIT- and PDGFRA-mutated kinases by regulating the kinase switch pocket and activation loop.MethodsPatients (pts) with advanced GIST who received prior treatment with at least imatinib, sunitinib, and regorafenib were enrolled. Pts were randomized 2:1 to ripretinib 150 mg QD or placebo (P) and stratified by 3 v ≥ 4 prior therapies and ECOG 0 v 1-2. Patients wit - 75PPulse mode irradiation regimen of PDT results in high progression free and overall survival in mice with model tumour
AbstractBackgroundPhotodynamic therapy (PDT) is one of actively developing modalities of cancer treatment. During PDT procedure systemically injected photosensitizer molecules are activated by laser irradiation in tumor location leading to generation of singlet oxygen which induces cytotoxic effect. In modern clinical practice PDT uses continuous wave irradiation. In such mode fast depletion of molecular (triplet) oxygen in tissue occurs leading - 231PThe changing landscape of breast cancer incidence after treatment for Hodgkin’s disease
AbstractBackgroundBreast cancer (BC) incidence increases after treatment for Hodgkin’s disease (HD). Over time, radiation techniques (RT) have reduced in dose and irradiated volume, and fewer alkylating (and gonadotoxic) chemotherapy (CT) agents used. We investigated BC incidence in the context of treatment changes over almost 4 decades and known risk factors.MethodsPubMed abstracts were identified using search terms ‘Hodgkin disease’, ‘Breast ne - 541PUpfront radical surgery with total mesorectal excision (TME) versus preoperative chemoradiotherapy followed by TME in clinical stage II/III patients with rectal cancer: A propensity score analysis
AbstractBackgroundAlthough the current standard preoperative chemoradiotherapy (PCRT) for stage II/III rectal cancer decreases the risk of local recurrence, it does not improve overall survival and increase the likelihood of preoperative overtreatment, especially in patients without the circumferential resection margin (CRM) involvement.MethodsStage II/III rectal cancer without CRM involvement and lateral lymph node metastasis was radiologically - LBA4_PRNivolumab (NIVO) + low-dose ipilimumab (IPI) vs platinum-doublet chemotherapy (chemo) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): CheckMate 227 part 1 final analysis
AbstractBackgroundPart 1 of CheckMate 227 (NCT02477826), a phase III study in 1L NSCLC, has dual primary endpoints. The primary endpoint of progression-free survival (PFS) with NIVO + IPI vs chemo in patients (pts) with tumor mutational burden ≥ 10 mut/Mb was met, as reported previously. Here we present the primary endpoint of overall survival (OS) for NIVO + IPI vs chemo in pts with tumor PD-L1 expression ≥ 1%.MethodsPts were chemo-naive, with s - 1674PDTrabectedin with concurrent low-dose of radiation therapy for metastatic soft tissue sarcomas: A phase II trial of Spanish, French and Italian sarcoma groups
AbstractBackgroundThe capacity of inducing tumor shrinkage in advanced soft tissue sarcomas (STS) is an unmet need beyond the first-line of systemic therapy. Pivotal studies of approved drugs reported RECIST response rates below 10%. Thus, it is challenging to relieve symptoms related to tumor volume in patients progressing to anthracycline-based schemes. Besides that, the overall response rate (ORR) is an appropriate surrogate for overall surviv - 1567PEfficacy of weekly paclitaxel-bevacizumab combination in advanced non squamous non-small cell lung cancer (NSCLC): A retrospective multicentric study
AbstractBackgroundULTIMATE, a phase III trial, showed a significant superiority in terms of progression free survival (PFS) and less toxicity of the combination paclitaxel-bevacizumab versus docetaxel as second or third-line treatment. With the growing role of immunotherapy as first-line setting for advanced non-small cell lung cancer (NSCLC), there is a need to redefine strategies to failure. The use of the paclitaxel-bevacizumab combination cou - 1671OAssessment of cardiotoxicity (CT) associated with doxorubicin (dox) in patients (pts) with advanced soft tissue sarcoma (STS) in a phase III randomized trial
AbstractBackgroundThe ANNOUNCE trial evaluated the efficacy of the anti-PDGFR alpha antibody olaratumab + dox versus placebo + dox in adults with STS. CT was a secondary safety objective.MethodsTreatment included dox 75mg/m2 on Day 1 of a 21-day cycle for up to 8 cycles, with olaratumab/placebo on Days 1, 8 until progression. Use of the cardioprotectant dexrazoxane was allowed with any cycle and recommended with Cycle 5 and beyond. Pts were monit - 1129PWindow of opportunity for durvalumab (MEDI4736) plus metformin trial in squamous cell carcinoma of the head and neck (SCCHN): Interim safety analysis
AbstractBackgroundDespite the application of PD-1 inhibitors in clinical practice in SCCHN, only a fraction of patients shows durable responses to monotherapy. Numerous combinatorial strategies have been utilized to attempt to augment immunotherapy efficacy. While dysregulated tumour metabolism (TM) is a critical feature of the tumour microenvironment (TME) and impacts immune function within the TME, much remains to be done to bridge these areas - 318PAssociation between PIK3CA mutation status and development of brain metastases in HR+/HER2- metastatic breast cancer
AbstractBackgroundCNS metastases is a devastating complication of breast cancer, occurring in approximately 10%–15% of patients with metastatic breast cancer (MBC) and resulting in median survival of less than one year in historic cohorts. Biological factors that govern metastases to the brain, including the role of activating PIK3CA mutations, the most common actionable alterations in HR+/HER2- MBC, are poorly understood.MethodsIn this retrospec - 230PBreast cancer incidence and survival in renal transplant patients: 35-year experience
AbstractBackgroundRenal transplantation is known to be associated with increased risk of malignancy. Concurrent presence of malignant diseases and transplantation may influence overall survival. This study summarizes our 35-year experience in breast cancer (BC) in renal transplant patients focusing on the incidence of BC and its impact on survival of this population.MethodsProspectively collected data of female patients treated with renal transpl - 313PGenome copy number alteration burden represents predictor of response in long-term, never relapse exceptional responders of trastuzumab-treated HER2+ metastatic breast cancer
AbstractBackgroundThe introduction of anti-HER2 therapies such as trastuzumab for HER2+ metastatic breast cancer (MBC) has led to significant improvements to disease progression. We, and others have reported cases of long-term durable complete response to trastuzumab in HER2+ MBC. However, to-date only clinical and molecular analysis of this “exceptional” cohort exists. We hypothesise that genomic copy number alteration (CNA) burden can act as a - LBA77Simultaneous multi-cancer detection and tissue of origin (TOO) localization using targeted bisulfite sequencing of plasma cell-free DNA (cfDNA)
AbstractBackgroundOur previous discovery work identified whole-genome bisulfite sequencing as outperforming whole-genome and targeted sequencing approaches for multi-cancer detection. We developed a targeted methylation assay for multi-cancer detection and tissue of origin (TOO) localization.MethodsParticipants were from Circulating Cell-free Genome Atlas (CCGA; NCT02889978) and STRIVE (NCT03085888), both prospective, multi-center, observational - 306PDPIK3CA alterations in metastatic breast cancer (mBC)
AbstractBackgroundThe anticipated approval of the first specific PIK3CA inhibitor, apelisib, has increased interest in the frequency and range of PIK3CA genomic alterations (GA) in the major subtypes of mBC.MethodsDNA was extracted from 3,871 mBC: 1,259 ER+/HER2-, 1,969 HER2 amplified (amp) and 643 TNBC. GA, tumor mutational burden (TMB) and microsatellite instability (MSI) were identified by hybrid-capture. PD-L1 was determined by IHC.ResultsPIK - 1128PFinal results of a phase II study of induction chemotherapy (CT) with paclitaxel (PTX) and panitumumab (P) followed by radiotherapy (RT) and P in patients (pts) with locally advanced head and neck cancer (LAHNC) no candidates to platinum: Study PANTERA
AbstractBackgroundPatients (pts) not candidates to platinum-based therapies have limited therapeutic options. The addition of P to PTX followed by RT + P may be an alternative to platinum-based therapy. This study aimed to evaluate the activity of P + PTX as induction treatment (Tx) in pts with LAHNC.MethodsPhase II, single arm, multicenter study, in pts≥18 years with CT/RT-naive stage III-IVb LAHNC not candidates to aggressive Tx. All pts receiv - 520PSafety of high doses of somatostatin analogs in well differentiated NENs in elderly
AbstractBackgroundNeuroendocrine neoplasms (NENs) are a group of heterogeneous neoplasms which can be treated with different therapies: in well differentiated (WD) NENs analogs of somatostatin (SSA) can be used considering their proved antineoplastic and antisecretory effects. This is a multicenter study to investigate the safety of high doses (HDD) analogs of somatostatin (SSA) in WD NENs with particular attention for patients over 70 years of a - 1566PRetrospective comparative study of the efficacy and safety in docetaxel and ramucirumab combination chemotherapy with or without previous immune checkpoint inhibitor treatment
AbstractBackgroundSalvage chemotherapy after immune checkpoint inhibitor (ICI) treatment has been reported to increase the antitumor effect. There are also some reports that activation of vascular endothelial growth factor (VEGF) / its receptor (VEGFR) signal is one of the ICI resistant mechanism, and that combination therapy of VEGF / VEGFR inhibitor and ICI had synergistic effect. In ICI pretreated patients, docetaxel and ramucirumab combinatio - 1186PDSafety and efficacy of the oral CXCR4 inhibitor X4P-001 + axitinib in advanced renal cell carcinoma patients: An analysis of subgroup responses by prior treatment
AbstractBackgroundThe CXCR4 chemokine receptor modulates immunosuppressive cell trafficking that can inhibit antitumor immune responses. X4P-001 is a selective, oral CXCR4 antagonist currently in clinical development as a novel therapy for solid tumors, including renal cell carcinoma (RCC). In xenograft models, X4P-001 in combination with axitinib, a VEGF receptor tyrosine kinase inhibitor (TKI), reduced myeloid-derived suppressor cell infiltrati - 229PImpact of education for breast self examination in rural Indian women on early detection: Results of POC study
AbstractBackgroundBreast cancer contributes to 19-34% of all malignancies- indicating the high disease burden. In view of various socio-economic and cultural reasons, patients usually present at an advanced stage because of lack of awareness and nonexistent breast cancer screening programs in India. Breast self-examination (BSE) is easy cost effective and proven way for early detection.MethodsObjective: 1. To train women for Breast self-examinati - 511TiPA phase I, open-label study of GSK1795091 administered in combination with immunotherapies in participants with advanced solid tumours (NCT03447314)
AbstractBackgroundToll-like receptor (TLR) activation can enhance a range of antitumor immune responses via production of inflammatory cytokines and modulation of immune cells in the tumor microenvironment. GSK1795091 is a synthetic TLR4 agonist that showed immunomodulatory activity in preclinical cancer models (Gao et al. J Clin Oncol 2018) and successfully completed a safety, pharmacokinetic (PK) and pharmacodynamic (PD) study using IV administ - LBA76Efficacy and safety of surufatinib in patients with well-differentiated advanced extrapancreatic neuroendocrine tumors (NETs): Results from the randomized phase III study (SANET-ep)
AbstractBackgroundSurufatinib (HMPL-012, previously named sulfatinib) is a small-molecule kinase inhibitor targeting vascular endothelial growth factor receptors, fibroblast growth factor receptor 1 and colony stimulating factor 1 receptor, which demonstrated encouraging efficacy in previous Phase Ib/II study in patients with advanced NETs regardless of tumor origin.MethodsThis was a randomized, double-blind, multi-center phase III study to evalu - 1632PDDeterminants of the cancer drug funding process in Canada
AbstractBackgroundCanada has a publicly-funded healthcare system with a complex drug funding process. After Health Canada approval to market a drug, the pan-Canadian Oncology Drug Review (pCODR) makes a non-binding funding recommendation to the Canadian provinces (except Quebec), which each then decide whether the drug will be publicly funded. We identified the determinants of funding in this process.MethodsWe analyzed drugs for advanced lung (n - 1127PBrachytherapy and non-cancer mortality in patients with oral cavity and oropharynx SCCs
AbstractBackgroundOral cavity and oropharyngeal squamous cell cancers (OC-OPSCC) display high cancer mortality. Aspiration, infection, other complications or treatment, and age- and substance-related comorbidities contribute to non-cancer mortality. This single-institution study examines cause of death in patients treated for OC-OPSCC with brachytherapy, chemotherapy, external beam radiation, surgery, or combination of modalities. We hypothesize - 504PAVID200 neutralizes TGF-beta1 and -beta3, the principal immunosuppressive TGF-beta isoforms overexpressed by tumours, and sensitizes tumours to immune checkpoint inhibitors
AbstractBackgroundResistance to immune checkpoint inhibitors (ICIs) is a major unmet medical need. The TGF-beta pathway is a key immunosuppressive mechanism that correlates with resistance to PD-1/PD-L1 inhibitors. TGF-beta acts by inhibiting the recruitment and activation of anti-tumor T-cells, either directly, or indirectly through its action on cancer-associated fibroblasts. AVID200 is a receptor ectodomain trap that was rationally-designed to - 228PEffects of aerobic and resistance exercise on android: Gynoid fat ratio in breast cancer survivors
AbstractBackgroundThe android:gynoid percent fat ratio (AGFR) is associated with increased risk of cardiovascular disease and type 2 diabetes in breast cancer survivors (BCS). Exercise reduces fat mass in BCS; however, few studies have focused on AGFR. The study purpose was to examine the effects of a 16-week aerobic and resistance exercise intervention on AGFR among BCS. We assessed whether exercise-induced changes in AGFR were associated with i - 40PVascular endothelial growth factor in colorectal cancer pathology, survival and treatment
AbstractBackgroundAngiogenesis (the growth of new blood vessels) is important for tumour invasion and metastasis in order for a tumour to grow beyond a few millimetres in size. Vascular endothelial growth factor (VEGF) is thought to be the predominant angiogenic factor in colorectal and other cancers. As a result, numerous studies have looked at VEGF expression in colorectal cancer patients and several therapeutic agents have been trialled that t - LBA7518-months relapse-free survival (RFS) and biomarker analyses of OpACIN-neo: A study to identify the optimal dosing schedule of neoadjuvant (neoadj) ipilimumab (IPI) + nivolumab (NIVO) in stage III melanoma
AbstractBackgroundPrimary analysis of the OpACIN-neo study testing 3 dosing schedules of neoadj IPI+NIVO identified 2 cycles IPI 1 mg/kg + NIVO 3 mg/kg (IPI1+NIVO3; arm B) as most favourable, with 20% grade 3-4 irAEs and a pathologic response rate (pRR) of 77%. After a median FU of 8.3 mo none of the pts with a pathologic response versus 9/21 (43%) of the non-responders had relapsed. Here we present updated RFS and biomarker analyses.MethodsOpACI - 499PIdentification of first-in-class, naturally occurring LAG3 checkpoint inhibitor
AbstractBackgroundDespite the impressive impact of CTLA4 and PD-1/L1 cancer immunotherapy, a large proportion of patients with many tumor types fail to respond. Lymphocyte activation gene 3 (LAG3) is the third checkpoint receptor that plays an important role in the pathogenesis of cancer. We have previously described a novel methodology in the identification of therapeutic antibodies (US Patent #9810694). Here we report the discovery of first-in- - 1126PTreatment outcomes of head and neck cancer patients 70 years and older receiving different chemo-radiation combinations
AbstractBackgroundConcurrent chemoradiation (CRT) improves survival in squamous cell carcinoma of the head and neck (HNSCC). Little is known about the outcomes of elderly patients (pts, ≥70 years old) in terms of treatment efficacy and side effects. This retrospective study compares acute toxicity, response to therapy, and overall survival between elderly pts receiving different CRT combinations.MethodsPts. without dementia, deficit on instrument - 1167PClassification of esthesioneuroblastoma (ENB) based on chromosome (chr) arm gain and loss (CNA) in the setting of a hypomutated genomic landscape
AbstractBackgroundENB is a rare skull base tumor arising from the olfactory neuroepithelium with variable prognosis and no consensus guidelines for treatment. Previous genomic studies (Classe 2018, Capper 2018) have reported scant genomic alterations (GA) in advanced and metastatic ENB (mENB), including mutation of IDH2. Here, we explore the cytogenetic landscape of in 94 cases of mENB as assessed by NGS-based comprehensive genomic profiling (CGP - 227PBaseline quality of life (QoL) and chemotherapy related toxicities (CRT) in localized breast cancer (BC) patients (pts): The French multicentric prospective CANTO cohort study
AbstractBackgroundIn this study we aimed to examine the independent effect of baseline QoL and persistent CRT among pts with early BC.MethodsWe included data stage I-III BC pts treated with chemotherapy who were included in the CANTO prospective cohort study (NCT-01993498) from 03/2012 to 12/2014. The primary outcome was CRT defined as the presence at 3-6 months after the end of treatment, of any of the following toxicities (NCI-CTC-AE): infectio - 1611PSpecialist palliative care (SPC) in haematological malignancy: Establishing practices in a UK tertiary cancer centre (TCC)
AbstractBackgroundInternational consensus supports early integration of SPC in oncological disease. Haematological malignancies differ in nature from solid site tumours. Remitting and relapsing trajectories, late salvage treatments, and divergent outcomes make for difficult prognostication and traditional markers of ‘good’ end of life care may not translate well to this group. However, disease is often incurable and physical and psychological sym - LBA74Phase II study of neoadjuvant cemiplimab prior to surgery in patients with stage III/IV (M0) cutaneous squamous cell carcinoma of the head and neck (CSCC-HN)
AbstractBackgroundCutaneous squamous cell carcinoma (CSCC) harbors a high tumor mutation burden (TMB) due to ultraviolet light-mediated DNA damage, and are highly immune-responsive. Cemiplimab, a monoclonal antibody directed against programmed death 1 (PD-1), is approved by the FDA and EMA as treatment for advanced CSCC patients who are not candidates for curative surgery. Here we explore the efficacy of neoadjuvant cemiplimab in CSCC- head and n - 270PEvaluation of germ line mutational status among women with triple-negative breast cancer in Russia
AbstractBackgroundPathogenic germline BRCA1/2 mutations are found in higher rates in patients with triple negative breast cancer (TNBC). As a result, genetic BRCA mutation testing would be beneficial for this particular group of patients. At the same time, it is less clear if mutational burden in other cancer predisposition genes is more frequent in TNBC and has to be recommended for genetic testing. In the current study we aimed to characterize - 1125PRadiotherapy plus cisplatin (CDDP) or cetuximab (C225) in human papilloma-virus (HPV)-associated oropharyngeal cancer (OPC)? A dilemma finally resolved. An updated meta-analysis
AbstractBackgroundHuman papilloma virus (HPV)-associated oropharyngeal cancer (OPC) is a special entity among head and neck squamous cell carcinomas (HNSCCs) characterised by higher survival rates compared to similar stage HPV-negative OPC. Due to favorable prognosis, a significant interest in ‘’less toxic’’ therapies (de-escalating strategies) in the treatment of HPV-associated OPC had been introduced. One of the approaches included introduction - 25PPaired-related homeobox 1 overexpression promotes invasion and metastasis and is a prognostic factor for worse disease-free survival in patients with lung cancer
AbstractBackgroundLung cancer is the main cause of cancer-related death worldwide. Epithelial-mesenchymal transition (EMT) is one of the major molecular mechanisms inducing tumor invasion and metastasis. Paired-related homeobox 1 (Prrx1) is a newly found EMT-inducing transcription factor. The prognostic value of Prrx1 in lung cancer has not been well demonstrated.MethodsH1299-Prrx1 cell lines were generated by transfecting the pcDNA3.1-Prrx1 plas - 226PEvaluation of endocrine therapy and patients preferences in early breast cancer: Results of Elena study
AbstractBackgroundHormonal therapy (HT) is generally proposed to all patients with endocrine receptor positive breast cancer to reduce the risk of recurrence and death. However, HT is associated with side effects. The aim of the present study was to determine the preferences of women treated with adjuvant HT for breast cancer.MethodsPreferences have been elicited with a self-completed, validated questionnaire administered at study entry in eligib - 480PDrug-drug interaction profile of tepotinib with CYP3A and P-gp substrates
AbstractBackgroundTepotinib is an oral, highly selective MET inhibitor being investigated in MET-driven solid tumors. Cancer patients often receive co-medications, many of which are subject to cytochrome P450 3A (CYP3A) or P-glycoprotein (P-gp)-dependent pharmacokinetics.The potential of tepotinib to alter the exposure to such drugs was investigated in two clinical drug-drug interaction (DDI) trials.MethodsThe effect of multiple doses of the RP2D - LBA73SELPAC: A 3 arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel (PT) in metastatic uveal melanoma (UM)
AbstractBackgroundThe MAPK pathway is constitutively activated in uveal melanoma (UM), a disease for which there remains no standard of care for metastatic disease. In a randomised phase II clinical trial, selumetinib (AZD6244, ARRY-142886), a MEKi, showed superiority vs dacarbazine (DTIC). A phase III study of the combination of selumetinib (SEL) + DTIC however failed to show superiority over DTIC alone. Pre-clinical data support synergistic cyt - 20PMatrix metalloproteinases and their tissue inhibitors genes abnormal DNA methylation in breast cancer
AbstractBackgroundMatrix metalloproteinases (MMPs) specifically hydrolyze the extracellular matrix proteins. MMPs are inhibited by tissue inhibitors of MMPs (TIMPs). Changes in the expression levels of MMPs and TIMPs have been described in various cancers, including breast cancer (BC).MethodsWe analyzed methylation status of 11 MMP genes (MMP2, MMP11, MMP14, MMP15, MMP16, MMP17, MMP21, MMP23B, MMP24, MMP25, MMP28) and 4 TIMP genes (TIMP1, TIMP2,
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου